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introduction: We retrospectively evaluated the efficacy and toxicity of gross tumor vol-
ume (GTV) mean dose optimized stereotactic body radiation therapy (SBRT) for primary 
and secondary lung tumors with and without robotic real-time motion compensation.
Materials and methods: Between 2011 and 2017, 208 patients were treated with 
SBRT for 111 primary lung tumors and 163 lung metastases with a median GTV of 
8.2 cc (0.3–174.0 cc). Monte Carlo dose optimization was performed prioritizing GTV 
mean dose at the potential cost of planning target volume (PTV) coverage reduction while 
adhering to safe normal tissue constraints. The median GTV mean biological effective 
dose (BED)10 was 162.0 Gy10 (34.2–253.6 Gy10) and the prescribed PTV BED10 ranged 
23.6–151.2 Gy10 (median, 100.8 Gy10). Motion compensation was realized through direct 
tracking (44.9%), fiducial tracking (4.4%), and internal target volume (ITV) concepts with 
small (≤5 mm, 33.2%) or large (>5 mm, 17.5%) motion. The local control (LC), progression- 
free survival (PFS), overall survival (OS), and toxicity were analyzed.
results: Median follow-up was 14.5 months (1–72 months). The 2-year actuarial LC, 
PFS, and OS rates were 93.1, 43.2, and 62.4%, and the median PFS and OS were 
18.0 and 39.8 months, respectively. In univariate analysis, prior local irradiation (hazard 
ratio (HR) 0.18, confidence interval (CI) 0.05–0.63, p = 0.01), GTV/PTV (HR 1.01–1.02, 
CI 1.01–1.04, p < 0.02), and PTV prescription, mean GTV, and maximum plan BED10 
(HR 0.97–0.99, CI 0.96–0.99, p < 0.01) were predictive for LC while the tracking method 
was not (p =  0.97). For PFS and OS, multivariate analysis showed Karnofsky Index 
(p < 0.01) and tumor stage (p ≤ 0.02) to be significant factors for outcome prediction. 
Late radiation pneumonitis or chronic rip fractures grade 1–2 were observed in 5.3% of 
the patients. Grade ≥3 side effects did not occur.
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conclusion: Robotic SBRT is a safe and effective treatment for lung tumors. Reducing 
the PTV prescription and keeping high GTV mean doses allowed the reduction of toxicity 
while maintaining high local tumor control. The use of real-time motion compensation 
is strongly advised, however, well-performed ITV motion compensation may be used 
alternatively when direct tracking is not feasible.
Keywords: non-small cell lung cancer, lung metastases, gross tumor volume optimization, Monte carlo, 
stereotactic body radiation therapy, cyberKnife robotic radiosurgery
inTrODUcTiOn
For primary and secondary lung tumors, various treatment 
options are available, their efficacy mostly depends on tumor and 
metastatic stage (1–4). The primary treatment option with cura-
tive intent for early stage non-small cell lung cancer (NSCLC) or 
oligo-lung-metastases remains surgery. For inoperable patients, 
however, stereotactic body radiation therapy (SBRT) is the pri-
mary method of choice with curative intent (4–9), while other 
minimal-invasive local ablative therapies cannot be considered 
curative for the majority of patients (1, 10). Because of the 
reported high local control (LC) rates with low toxicity (4–10), 
SBRT has even been investigated as potential curative treatment 
option for operable patients (11) and is increasingly considered as 
a viable alternative to surgery in some circumstances (12).
The principle of SBRT is to deliver high biological effective 
doses (BEDs) (13) with sharp dose gradients to spare tumor 
surrounding organs at risk. To achieve the necessary treatment 
accuracy for high doses, especially in moving organs like the lung, 
various motion management concepts have been implemented 
(14–16). Today, many treatment platforms can adequately plan 
(17) and accurately deliver (18) high-quality SBRT. Robotic-
guided real-time tumor tracking with the CyberKnife® (Accuray 
Incorporated, Sunnyvale, CA, USA) (19, 20) is a dedicated sys-
tem that offers the required accuracy for SBRT. For lung tumor 
tracking, the initial implementation of tumor localization by 
stereoscopic kilo-voltage imaging and 2D/3D image registration 
required the insertion of small gold marker. This poses the risk of 
inducing side effects before treatment (21, 22) and invalidates the 
non-invasive approach of SBRT.
Further development on fiducial-less and hence fully 
non-invasive tumor localization (XSight Lung®, Accuray) has 
overcome those limitations that are particularly relevant to multi-
comorbid patients (23, 24). Yet, not all lesions are eligible for 
fiducial-less tracking (25). On the other hand, in cases where the 
tumor motion is relatively limited (e.g., in the upper lungs), the 
use of an internal target volume (ITV) to cover the tumor motion 
range and hence accepting higher lung doses may be an adequate 
alternative treatment technique (14, 15, 26) if direct tracking is 
not feasible. Since volumetric imaging for robotic SBRT has only 
Abbreviations: SBRT, stereotactic body radiation therapy; GTV, gross tumor 
volume; CTV, clinical target volume; ITV, internal target volume; PTV, planning 
target volume; CT, computer tomography; PET, positron emission tomography; 
BED, biological effective dose; TCP, tumor control probability; LC, local control; 
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confi-
dence interval.
been introduced recently (27), ITV concepts for the CyberKnife 
often relies on tracking the spinal skeleton (XSight Spine®, 
Accuray) (28). Yet it is well known that lung tumors may vary its 
baseline position with respect to the spinal column (29, 30) and 
the clinical impact of using XSight Spine for lung tumors has not 
been investigated until recently (31).
Specific to lung SBRT, the uncertainties of dose calculation 
in the presence of large tissue heterogeneity adds another layer 
of complexity onto target localization (32–34). Therefore, type-b 
dose calculation by Monte Carlo (MC) simulation (35) or even 
prescription based on MC dose (36) is strongly advised. However, 
there has been only little evidence as to how the exact internal 
tumor dose distribution correlates with the treatment outcome. 
Besides standard planning target volume (PTV) prescription 
and maximum plan dose were found to influence the treatment 
outcomes (5, 13, 17), a few studies further suggested that mean 
dose to the gross tumor volume (GTV) may also be relevant for 
outcome prediction (37–39). Nonetheless, the GTV mean dose 
has to be explicitly optimized when using the small collimated 
beams of the CyberKnife (38, 39), otherwise dose valleys may 
arise in the central tumor region. This is also true for heteroge-
neous tissues, even though the dose may already be somewhat 
centered due to build-up effects.
Similar to our treatment method for liver metastases (38), our 
approach for lung tumors, regardless of the tracking method, 
was to maximize the MC dose within the GTV at the potential 
cost of PTV coverage reduction while adhering to safe normal 
tissue constraints. The aim of our retrospective analysis for LC, 
progression-free survival (PFS), overall survival (OS), and toxic-
ity was now to validate our GTV-optimized treatment approach 
based on the different tracking techniques for robotic SBRT and 
compare the results to previously published literature.
MaTerials anD MeThODs
Patient characteristics
This retrospective analysis was approved by the respective ethics 
committees of the treating centers. Between January 2011 and 
January 2017, 104 patients with a total of 111 primary inoperable 
lung tumors and 104 patients with a total of 163 inoperable lung 
metastases (one to four lesions per patient) were treated with 
SBRT using the CyberKnife system in 214 series at two method 
and quality matched centers performing radiosurgery (Table 1). 
In 173 (80.8%) series, a solitary lesion was treated while in 
27 (12.6%), 9 (4.2%), and 5 (2.4%) series, two, three, and four 
lesions were treated simultaneously.
TaBle 1 | Patient, tumor, and treatment characteristics.
Total %
Patients 208
With primary lung tumors 104 50.0
With lung metastases 104 50.0
Gender
Male 140 67.3
Female 68 32.7
Age
Median (range) in years 69 (26–87)
Karnofsky Index
Median (range) in % 90 (60–100)
Lesions 274
Primary lung tumors 111 40.5
Early stage 55 20.1
Recurrent early stage 13 4.7
Advanced stage 43 15.7
Lung metastases 163 59.5
Primary tumors (metastatic patients)
Lung 34 32.7
Colorectal 32 30.8
Renal 7 6.7
Breast 5 4.8
Other 26 25.0
Treatments
1 lesion 173 80.8
2 lesions 27 12.6
3 lesions 9 4.2
4 lesions 5 2.4
Re-irradiation
After radiotherapy 6 2.8
After SBRT 6 2.8
GTV
Median (range) in cc 8.2 (0.3–174.0)
PTV
Median (range) in cc 18.0 (1.6–448.0)
PTV dose per lesion (all Monte Carlo)
1 × 18–26 Gy 27 9.9
3 × 7–13 Gy 52 19.0
3 × 14–15 Gy 99 36.1
3 × 16–18 Gy 45 16.4
5 × 5–11 Gy 29 10.6
Other concepts 22 8.0
PTV prescription BED
Median (range) in Gy 100.8 (11.2–151.2)
GTV mean BED
Median (range) in Gy 160.5 (17.1–253.6)
Motion compensation
Direct tracking 135 49.3
Median (range) GTV in cc 11.5 (0.7–154.0)
ITV concept (≤5 mm motion) 91 33.2
Median (range) GTV in cc 10.0 (0.7–174)
ITV concept (>5 mm motion) 48 17.5
Median (range) GTV in cc 2.0 (0.3–96.3)
GTV, gross tumor volume; PTV, planning target volume; ITV, internal target  volume; 
BED, biological effective dose with α/β-ratio of 10 Gy; SBRT, stereotactic body  
radiation therapy.
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Of the 111 primary lung tumors, 55 (49.6%) were considered 
newly diagnosed early stage NSCLC. One patient was treated 
simultaneously for three synchronous NSCLC, and two patients 
were treated simultaneously for two synchronous NSCLC (dif-
ferent histology). Furthermore, 13 (11.7%) lung tumors were 
considered locally recurrent early stage NSCLC after initial 
surgery and 43 (38.7%) were considered locally recurrent or 
systemically controlled advanced stage lung cancer after initial 
chemo- and/or targeted-therapy. Of the 43 advanced stage 
patients, 4 were treated simultaneously for the primary tumor 
and a solitary lung metastasis.
The primary tumors of the 104 metastatic patients were mainly 
lung and colorectal cancer (32.7 and 30.8%, respectively) and all 
but the above-mentioned four primary tumors were controlled 
at the time of SBRT for the lung metastases. All patients were 
considered oligometastatic having less than five metastatic sites.
For all primary lung tumors and lung metastases, robotic 
SBRT was used for local in-field recurrences after initial con-
ventional radiotherapy (range, 60–72  Gy10) or SBRT (range, 
72–155 Gy10) for six lesions each. Median patient age was 69 years 
(range, 26–87 years), baseline Karnofsky Index was 90% (range, 
60–100%), and median GTV was 8.2 cc (range, 0.3–174.0 cc).
Treatment Preparation
Prior to treatment, simulation on the CyberKnife system was per-
formed to determine if the according lesion can be located with 
the fiducial-less 3D motion compensation system (XSight Lung). 
If that was not the case, the lesion location (proximal or distal to 
the spinal column) and the likelihood of motion (≤ or >5 mm) 
were classified to determine if the lesion can be safely treated 
using the spine tracking system (XSight Spine) with minimal 
additional safety margins. If that was also not the case, the patient 
was informed on the possible use of larger motion management 
margins or fiducial implantation close to the lesion. For the 
latter, a single GoldAnchor™ (Naslund Medical AB, Huddinge, 
Sweden) with a 25-G needle was implanted as close to the lesion 
as possible under computer tomography (CT) guidance.
Treatment Planning
Treatment planning was performed on standard non-contrast-
enhanced CT scans with 1.5 mm slice thickness at regular end 
expiration breath hold for XSight Lung and at regular breathing 
mid phase for XSight Spine tracking. For XSight Spine, the 
planning CT was fused with regular end expiration and end 
inspiration breath hold CT. The GTV was defined using CT 
lung windowing according to common standard practice (6, 21). 
Secondary fusion of positron emission tomography (PET)-CT 
for GTV definition was performed whenever available and for all 
locally recurrent lesions after initial therapy. The clinical target 
volume (CTV) consisted of the GTV with an expansion of 2 mm 
in all directions within the lung (excluding extension beyond lung 
parenchyma) to encompass microscopic tumor spread (21, 40). 
For XSight Spine tracking, the internal  target volume (ITV) 
was defined as interpolated composite of CTVs on expiration, 
mid phase, and inspiration planning CT for adequate motion 
compensation during treatment (Figure 1, right). For dual lesions 
close to each other, the ITV of the non-tracked lesion was defined 
as differential location composite of CTVs in comparison to the 
registered CTV of the tracked lesion (Figure 1, bottom).
The PTV included the CTV/ITV and an expansion of 3 mm 
in all directions to encompass the targeting uncertainties for 
the CyberKnife system (20, 41). For strong moving and highly 
FigUre 1 | CyberKnife tracking methods for lung tumor treatment. Gross tumor volume (GTV) in red, 2 mm clinical target volume margin in yellow, 3 mm planning 
target volume in light blue, treatment beams in green, and motion indicated using transparency colors. Top left: direct tumor tracking throughout the respiratory 
cycle with planning on end expiration breath hold using relatively smaller beams compared to GTV. Top right: motion compensation with internal target volume (ITV) 
concept using relatively larger beams compared to GTV. Bottom: direct tumor tracking for left lesion and indirect tumor tacking with differential motion margin (dark 
blue) for right lesion using similar sized beams compared to GTV.
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deformable lesions as well as for XSight Spine tracking for lesions 
further away from the spinal column, an additional PTV margin 
of 2 mm in all directions was applied (29, 30, 33).
Beam optimization was performed using MultiPlan® (Accuray, 
versions 3.5 and 4.5) utilizing Sequential Multi-Objective Opti-
mization (42) according to the consensus guidelines for treat-
ment planning for robotic radiosurgery (43). For XSight Spine 
tracking, beam aperture size selection was generally larger than 
the GTV dimension to avoid interplay effects (28, 34). Initial dose 
calculation for optimization was performed using the standard 
RayTrace dose algorithm at approximately 30% higher dose (35) 
as initial direct MC optimization is not feasible with MultiPlan. 
After initial beam optimization, the dose was re-calculated 
with the MC dose algorithm (44) using 2% uncertainty and re-
optimized to the desired dose distribution (Figure 2). Final dose 
calculation was based on MC with 1% uncertainty.
Regardless of the tracking method, the main objectives for 
MC optimization were to maximize the GTV mean dose above 
3 ×  21.5  Gy (BED10 =  203.2  Gy10) for early stage NSCLC and 
above 3 × 20.0 Gy (BED10 = 180.0 Gy10) for lung metastases, to 
cover 95% of the PTV with 3 × 15 Gy with a maximum dose of 
3 × 23 Gy [equivalent to 65% isodose prescription (6, 17)]. Also, 
doses to all critical structures were minimized according to the 
As Low As Reasonably Achievable principle. The prescription 
dose was initially increased to 3 × 16–18 Gy in 16.4% of the cases 
at the beginning of our series based on previous publications 
(35), but quickly lowered to 3 × 14–15 Gy (36.1% of the cases) 
due to newly published guidelines (6). The prescription dose was 
further lowered (3 × 7–14 Gy) in 27.3% of the cases and/or more 
protracted fractionation schedules were used (4–8 fractions) in 
18.6% of the cases (Table 1) when 3 × 14–18 Gy was not achiev-
able for the PTV due to critical organ constraints (Figure 2) (45). 
In 9.9% of the cases, a single fraction treatment was used, if the 
lesion was small enough according to published guidelines (46).
The aim of the PTV dose reduction was to maintain a 
high GTV mean dose without raising the maximum dose as 
previously published (38, 39). The final prescribed dose to the 
PTV ranged between 18.0 and 53.0  Gy (median 42.0  Gy) to 
the 55–85% isodose (median 69%) in 1–8 fractions (median 3 
fractions) and the mean GTV dose ranged between 20.5 and 
73.7 Gy (median 57.0 Gy), which resulted in a median BED10 
of 100.8 Gy10 (range, 23.6–151.2 Gy10) surrounding 95% of the 
PTV and of 162.0 Gy10 (range, 34.2–253.6 Gy10) for the mean 
GTV (Table 1).
FigUre 2 | Example for mean GTV Monte Carlo (MC) dose re-optimization for a peripheral early stage non-small cell lung cancer. Initial optimization with Ray Trace 
algorithm for 3 × 20 Gy and chest wall sparing (step 1, top left), re-calculation with MC algorithm with significant high dose (>60 Gy isodose) reduction in the tumor 
(step 2, top right), re-normalization with MC algorithm to 3 × 15 Gy to 65% isodose according to Ref. (6, 13, 17). with chest wall dose constraint [V30 Gy < 30 cc  
(6, 17)] violation and only 58 Gy mean GTV dose (step 3, bottom left), and re-optimization with MC algorithm to 60 Gy mean GTV dose and 3 × 14 Gy to 60% 
isodose in order to meet chest wall dose constraints (step 4, bottom right).
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Treatment Delivery
All patients were loosely immobilized using a custom-made 
vacuum mattress (HEK Medical, Germany) and initially aligned 
using the spinal vertebra closest to the lesions. SBRT was 
delivered using the XSight Lung and the Synchrony® Fiducial 
Respiratory Tracking System (Accuray, versions 8.5 and 9.5) for 
123 (44.9%) and 12 (4.4%) lesions, respectively (Table 1). This 
included three cases where a close (<1  cm) secondary lesion 
was simultaneously treated with XSight Lung and a differential 
motion margin (Figure  1, bottom). Respiratory motion was 
modeled, updated, and compensated during beam-on periods 
using the prediction of two to three LED chest markers which 
were correlated to the lesion directly or to the previously 
implanted gold fiducial marker detected on stereo x-ray imaging 
(19, 20, 23, 41). Combined average tracking errors (i.e., correla-
tion and predictions errors) were kept below 1 mm according to 
best practice guidelines (23, 41). Baseline rotation differences 
were compensated for using the spine alignment information, 
however, only for the patients treated with XSight Lung.
The ITV motion management concept was realized for 
91 (33.2%) and 48 (17.5%) lesions with ≤ and >5 mm motion, 
respectively. Prior to treatment start and after initial spine align-
ment an XSight Lung validation plan was utilized to visually 
inspect anatomy or lesion location changes if possible on the 
stereo x-ray imaging system. During treatment, the 6D (transla-
tion and rotation) XSpine tracking system (Accuray, versions 8.5 
and 9.5) was used with periodic (30–60 s) position verification 
and correction (47). Median fraction treatment time was 40 min 
(range, 13–73 min), excluding setup time.
Follow-Up and statistical analysis
All patients were observed 6–8  weeks after the end of their 
SBRT treatment and every 3 months thereafter. Every follow-up 
included the recording of possible adverse events according to 
the Common Terminology Criteria for Adverse Events (version 
4.03) for acute toxicity and the Radiation Therapy Oncology 
Group (RTOG) and European Organization for Research and 
Treatment of Cancer criteria for late toxicity. Imaging during 
follow-up was kept similar to the planning imaging and evalu-
ated using the response evaluation criteria in solid tumors with 
a dedicated focus on differentiation of radiation effects in the 
lung vs. actual tumor growth. Co-registration of the follow-up 
6Baumann et al. Mean GTV Dose Optimized SBRT
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images with the treatment plan was performed on a regular 
basis.
In our statistical analysis, we evaluated LC, PFS, OS, 
and toxicity. LC was defined as complete remission, partial 
remission, or stable tumor size (ST) and was independently 
confirmed by PET imaging or histology when CT gave suspi-
cious but inconclusive results. All time points for LC, PFS, and 
OS were calculated from the end of SBRT treatment to the 
respective event; death of any cause was the endpoint for OS. In 
case of multiple SBRT treatments, PFS and OS were calculated 
from the end of the first SBRT series and for LC each lesion 
was observed separately from the end of the respective SBRT 
treatment. In case of local recurrence, time to first description 
of suspected recurrence (back dating) was recorded. Surviving 
patients without a disease progression were censored at last 
follow-up. All curves were estimated using the Kaplan–Meier 
method.
The comparison of different patient, dosimetry, or tracking 
groups was performed using the log-rank-test for the univariate 
and using cox-regression for the multivariate analysis. For LC, 
among many other parameters, prior radiotherapy, histol-
ogy, GTV, PTV prescription, mean GTV and maximum dose 
expressed as BED10, and tracking was used as variables in the 
univariate analysis. For PFS and OS gender, age, Karnofsky Index, 
tumor stage, histology, prior treatment, and largest GTV were 
used as variables in the univariate analysis. Statistical analysis 
was performed for the whole patient group as well as for the 
subgroups (newly diagnosed and recurrent early stage NSCLC, 
advanced staged lung cancer and lung metastases).
For the indication of statistical significance, a p-value of <0.05 
was considered. Kaplan–Meier survival estimates and curves and 
univariate and multivariate analysis were calculated using the 
statistical program SPSS (version 20.0, IBM, Armonk, NY, USA).
resUlTs
At the time of analysis, the median follow-up for all patients after 
each SBRT treatment was 14.5  months (range, 1–72  months). 
Censoring for 1 and 2 years was 23.3 and 71.0%.
local control
Local control was analyzed per treated lesions (n = 274). The over-
all crude LC at time of analysis was 94.2%. The 2-year actuarial 
LC rate for all treated lung tumors was 93.1% (Figure 3). Median 
time to local failure was 14.6 months (range, 2.8–44.6 months). 
Out of the 17 local failures, 10, 6, and 1 occurred after robotic 
SBRT of lung metastases, advanced stage lung cancer, and recur-
rent early stage NSCLC while we did not see any local failure for 
robotic SBRT of newly diagnosed early stage NSCLC. Four local 
failures were marginal recurrences treated without the need for 
PTV dose reduction and those could have also been classified as 
logo-regional recurrences. The remaining 13 local failures were 
classified as in-field recurrences, of which three of them were 
treated with conventional radiotherapy prior to robotic SBRT. Six 
local recurrences were re-treated with SBRT, one recurrence was 
resected and ten recurrences were treated with further chemo- or 
targeted-therapy alone.
In univariate analysis for all lesions prior local irradiation 
[hazard ratio (HR) 0.18, 95% confidence interval (CI) 0.05–0.63, 
p =  0.01], GTV (HR 1.02, CI 1.01–1.04, p =  0.01), PTV (HR 
1.01, CI 1.01–1.02, p  =  0.02), PTV prescription BED10 (HR 
0.97, CI 0.96–0.99, p <  0.01), GTV mean BED10 (HR 0.98, CI 
0.97–0.99, p  <  0.01), and maximum lesion BED10 (HR 0.99, 
CI 0.98–0.99, p  <  0.01), the latter five variables considered 
as continuous variables, were predictive for LC (Table  2). 
Furthermore, univariate analysis based on median cutoff showed 
significant correlation between local failure and PTV prescrip-
tion BED10 < 100.8 Gy10 (HR 5.71, CI 1.81–17.96, p < 0.01), GTV 
mean BED10 < 162.0 Gy10 (HR 3.81, CI 1.22–11.89, p = 0.02), and 
maximum lesion BED10 < 197.0 Gy10 (HR 4.23, CI 1.35–13.26, 
p = 0.01), and the 2-year actuarial LC rates were 84.4 vs. 99.0, 
88.4 vs. 97.4, and 88.7 vs. 97.3%, respectively (Figure 3). Receiver 
operating characteristic analysis showed dose thresholds for LC 
for maximum lesion BED10 of 181 Gy10 for primary lung tumors 
(83.3 vs. 100.0%, p < 0.01) and 149 Gy10 for lung metastases (81.8 
vs. 96.9%, p = 0.02).
Tumor stage (early vs. advanced vs. metastatic), histology and 
tracking (XSight Lung/Fiducial Synchrony vs. ITV with ≤5 mm 
motion vs. ITV with >5 mm motion) in various combinations 
were all not predictive for LC when considering all lesions 
(Figure  3). In multivariate analysis with various models and 
thresholds, only prior local irradiation remained the predomi-
nant, though only borderline significant, factor for LC prediction 
(HR 0.22, CI 0.05–1.01, p = 0.052). However, the results of the 
multivariate analysis should also be interpreted with caution due 
to the limited number of local failure events (n = 17).
Progression-Free survival
Progression-free survival analysis was based on treated patients 
(n =  208). Overall, 100 (48.1%) patients were found to have 
disease progression at the time of analysis, 34 out of 104 (32.7%) 
after SBRT of primary lung tumors and 66 out of 104 (63.4%) 
after SBRT of lung metastases. Median PFS was 18 months and 
the 2-year actuarial PFS rate was 43.2% (Figure 3).
For the primary lung tumor patients with progression, median 
time to progression was 8.1  months (range, 0.9–68.0  months) 
and intra-pulmonary progression occurred in 18 (52.9%), intra-
cerebral progression in 8 (23.5%), intra-hepatic progression in 
4 (11.8%), bone progression in 3 (8.8%), and lymph-node progres-
sion in 1 (3.0%) case(s). Noteworthy, for newly diagnosed early 
stage NSCLC median time to progression after robotic SBRT was 
23.4 months (range, 5.0–68.0) and seven out of the nine patients 
with progression (16.4% overall progression based solely on early 
stage NSCLC patients) developed a new primary histologically 
different NSCLC, all of them re-treated with SBRT. For the lung 
metastases patients with progression, median time to progression 
was 7.6 months (range, 1.2–56.1 months) and intra-pulmonary 
progression occurred in 38 (57.6%), intra-cerebral progression 
in 9 (13.6%), lymph-node progression in 9 (13.6%), intra-hepatic 
progression in 6 (9.1%), and bone progression in 4 (6.1%) cases.
In univariate analysis for all patients, patient age at time of 
SBRT, gender, tumor histology, and prior local irradiation were 
not predictive for PFS (Table 2). On the other hand, disease stage 
(early stage vs. advanced stage vs. metastatic stage, p ≤  0.02), 
FigUre 3 | Left: Kaplan–Meier estimates for local control (LC), progression-free survival (PFS), and overall survival (top left), PFS stratified by primary lung tumors 
and lung metastases (top right), LC stratified by tracking method (bottom left), and LC stratified by mean gross tumor volume (GTV) biologically effective dose 
(bottom right).
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Karnofsky Index (≥80 vs. <80%, HR 0.03, CI 0.00–0.14, 
p <  0.01), and largest GTV (HR 1.01, CI 1.01–1.02, p <  0.01) 
had significant effects on the PFS in our analysis. In the subgroup 
analysis for primary lung tumors only, prior local irradiation 
(HR 0.29, CI 0.12–0.70, p = 0.01) was additionally predictive for 
PFS. In multivariate analysis with multiple models, disease stage 
and Karnofsky Index remained the only significant factors for 
outcome prediction (p ≤ 0.02).
Overall survival
Overall survival analysis was based on treated patients (n = 208). 
Overall, 104 (50.0%) patients have died at time of analysis, 54 
out of 104 (51.9%) after SBRT of primary lung tumors and 50 
out of 104 (48.1%) after SBRT of lung metastases. Median OS 
was 39.8 months for the whole group and the 2-year actuarial OS 
rate was 62.4% (Figure 3). Median OS for primary lung tumors 
and lung metastases alone was 32.7 (CI 26.5–38.9) months and 
41.8 (CI 37.2–46.4) months, respectively, the difference being 
significant (p < 0.01).
For the deceased primary lung tumor patients, median time to 
death was 10.5 months (range, 0.9–68.0 months) and death was 
mainly driven by cancer disease progression for advanced stage 
lung cancer patients and by co-morbidities for early stage NSCLC 
patients. For the deceased lung metastases patients, median time 
to death was 16.8 months (range, 0.4–61.1 months) and death was 
mainly driven by cancer disease progression.
In univariate analysis for all patients, gender, tumor histology, 
and prior local irradiation were not predictive for OS (Table 2). 
On the other hand, patient age at time of SBRT (HR 1.02, CI 
1.00–1.04, p  =  0.02), disease stage (early stage vs. advanced 
stage vs. metastatic stage, p <  0.01), Karnofsky Index (≥80 vs. 
<80%, HR 0.01, CI 0.00–0.02, p < 0.01), and largest GTV (HR 
1.02, CI 1.01–1.02, p < 0.01) had significant effects on the OS in 
our analysis. In the subgroup analysis for lung metastases only, 
TaBle 2 | Univariate and multivariate analysis for local control (LC), progression-
free survival (PFS), and overall survival (OS).
Univariate  
analysis
Multivariate 
analysis
hr (ci) p-Value hr (ci) p-Value
lc
Prior local irradiation 0.18 (0.05–0.63) 0.01 0.22 (0.05–1.01) 0.052
Histologya 0.72 (0.22–2.37) 0.59 n/a
GTVd 1.02 (1.01–1.04) 0.01 1.05 (0.95–1.16) 0.34
PTVd 1.01 (1.01–1.02) 0.02 0.98 (0.90–1.05) 0.52
PTV prescription BEDd 0.97 (0.96–0.99) <0.01 0.97 (0.92–1.02) 0.22
GTV mean BEDd 0.98 (0.97–0.99) <0.01 1.02 (0.98–1.06) 0.35
Maximum plan BEDd 0.99 (0.98–0.99) <0.01 0.99 (0.95–1.03) 0.35
Trackingb 1.13 (0.41–3.13) 0.81 n/a
PFs
Gender 0.83 (0.59–1.19) 0.32 n/a
Aged 1.00 (0.99–1.02) 0.92 n/a
Karnofsky Indexc 0.03 (0.00–0.14) <0.01 0.03 (0.00–0.20) <0.01
Early stage 0.22 (0.09–0.55) <0.01 0.20 (0.07–0.55) <0.01
Metastases 0.29 (0.13–0.68) <0.01 0.37 (0.15–0.87) 0.02
Histologya 1.43 (0.95–2.17) 0.09 1.53 (0.99–2.37) 0.06
Prior local irradiation 1.19 (0.86–1.65) 0.28 n/a
Largest GTVd 1.01 (1.01–1.02) <0.01 1.01 (1.00–1.03) 0.13
Os
Gender 1.15 (0.74–1.79) 0.54 n/a
Aged 1.02 (1.01–1.04) 0.02 1.02 (1.01–1.04) 0.053
Karnofsky Indexc 0.01 (0.00–0.02) <0.01 0.01 (0.00–0.13) <0.01
Early stage 0.20 (0.07–0.59) <0.01 0.17 (0.05–0.59) <0.01
Metastases 0.15 (0.05–0.43) <0.01 0.24 (0.07–0.76) 0.02
Histologya 2.24 (1.29–3.88) 0.00 2.34 (1.23–4.43) 0.01
Prior local irradiation 0.66 (0.31–1.42) 0.29 n/a
Largest GTVd 1.02 (1.01–1.02) <0.01 1.01 (0.99–1.03) 0.24
GTV, gross tumor volume; PTV, planning target volume; BED, biological effective dose; 
HR, hazard ratio; CI, 95% confidence interval.
aLung cancer vs. other primary cancer.
bDirect tumor tracking vs. internal target volume concept.
c<80 vs. ≥80%.
dEvaluated as continuous variables.
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patients with colorectal primary tumors (HR 1.87, CI 1.01–3.44, 
p = 0.05) had better OS, however, the patient numbers in each 
histology group were small, and this result has to be taken with 
caution. In multivariate analysis with multiple models, disease 
stage and Karnofsky Index remained the significant factors for 
survival prediction (p ≤ 0.02).
Toxicity
Fiducial implantation was generally well tolerated as all lesions 
were peripheral in the lung; however, 5 out of 12 (41.7%) patients 
developed a self-resolving minor pneumothorax requiring over-
night observation only. Overall, radiation treatment itself was 
also well tolerated. For centrally located lesions, toxicity was 
very low due to our PTV dose reduction concept and mild acute 
esophagitis or dyspnea grad 1–2 only occurred in nine patients 
(4.3%). Furthermore, one transient tumor bleeding without any 
clinical consequence was noticed for a re-irradiation patient. For 
all patients, late radiation pneumonitis grade 1–2 was observed 
in 10 patients (4.8%, 4 with XSight Lung, 6 with XSight Spine). 
Chronic rip fractures may be induced from SBRT (48, 49), how-
ever, in our series only one patient (0.5%) was found with a grade 2 
rib fracture at the time of analysis. Grade 3 or higher side effects 
did not occur.
DiscUssiOn
Currently, there is no consensus on how to optimize the dose 
distribution within the GTV or even the PTV and only limited 
consensus on how to prescribe the dose for lung SBRT besides to 
use type-b dose calculation algorithms (e.g., MC) (15–17, 35, 36). 
Some groups suggested prescription to the PTV at a particular 
isodose line (e.g., 3 × 15 Gy at the 65%) (6, 17) and some others 
suggested prescription to the GTV mean dose (e.g., 3 × 20 Gy 
to mean GTV) (36) in order to better homogenize treatment 
planning and enable plan comparison for lung SBRT. The latest 
published International Commission on Radiation Units and 
Measurements (ICRU) report 91 on prescribing, recording, and 
reporting of stereotactic treatments with small photon beams 
recommended the prescription to the PTV; however, they also 
acknowledged the reporting of median dose to the PTV and 
CTV/GTV and for heterogeneous tissues (i.e., the lung) (50). 
On the other hand, current RTOG clinical trial protocols allow 
for considerable dose inhomogeneity within the PTV and PTV-
encompassing isodose lines may even range from 60 to 90%, 
allowing for considerable differences in dose distributions! This 
becomes especially problematic with highly modulated treatment 
techniques like intensity/volumetric modulated radiation therapy 
or for the CyberKnife with its small non-isocentric non-coplanar 
beam arrangements.
Different to other groups previously (35, 36), our treatment 
planning approach has been to use MC dose re-optimization 
(not just re-calculation, compare Figure 2) and to prescribe the 
re-optimized MC dose to the PTV. While the prescription based 
on the PTV is strongly advised in the ICRU 91 report (50), the 
method of MC re-optimization was not explicitly advised as 
GTV overdosing may occur due to lack of lateral electron dis-
equilibrium and hence comparability of treatment outcome may 
be difficult. Opposite to that, we argue that GTV overdosing in 
each individual patient is explicitly desired to increase the tumor 
control probability (TCP) as long as the side effects are kept at 
a reasonable minimum. Therefore, our goal was to additionally 
optimize the dose distribution in order to achieve a high-dose 
plateau within the GTV as previously published (38, 39). This is 
generally not straightforward for the small CyberKnife beams, 
although the concentrically increasing dose in the target seems 
to be more obviously reached in the lung due to build-up 
effects. Furthermore, we optimized and prescribed the MC dose 
independent of the tracking method. The present retrospective 
study was designed to evaluate the efficacy and safety of our 
mean GTV dose optimized treatment planning method for lung 
tumors where we allowed the reduction of PTV prescription 
dose to adhere to safe normal tissue constraints using the robotic 
CyberKnife system.
First of all, our LC rates are well in line with results from 
previous series of lung SBRT and specifically CyberKnife SBRT 
(5, 7–9, 13, 21–24, 51–54). We found that the PTV prescription 
BED10 was a significant factor for LC which is in agreement with 
our previous and with large multi-institutional studies (5, 7–9, 
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13, 38, 39, 55, 56). In addition, we found a significant influence 
of GTV mean BED10 on LC, also confirming previous results 
(37–39). The 2-year actuarial LC was 99.0% for PTV ≥100.8 Gy10 
vs. 84.4% for PTV <100.8 Gy10 (p = 0.01) and 97.4% for mean 
GTV ≥162.0  Gy10 vs. 88.4% for GTV <162.0  Gy10 (p =  0.02) 
and noticeably no newly diagnosed early stage NSCLC locally 
recurred after robotic SBRT yet.
Our LC rates were found to be higher compared to previous 
CyberKnife lung publications with MC (35, 51–54). Interestingly, 
this finding was similar to our previous liver studies (38), albeit 
we seemingly used substantially lower PTV prescription doses 
and/or higher dose inhomogeneity. For comparison, Temming 
et al. (54) reported for early stage NSCLC (n = 106) treated with 
a similar method to ours a 2-year LC rate of 88% with doses far 
beyond 100.8  Gy10 (54). Contrary to this, we found 99.0% LC 
for ≥100.8 Gy10 for our entire cohort (n = 274) and 100.0% for 
the early stage NSCLC subgroup (n = 55). On the other hand, 
Temming et  al. did mention missing functional or histologic 
confirmation for some patients (54) and one cannot stress enough 
to confirm local disease progression after SBRT using advanced 
imaging techniques (57) or histology or at least to co-register the 
follow-up imaging to the treatment plan. Finally, the rate of side 
effects appears to be smaller in our cohort further suggesting that 
our method may notably increase TCP while reducing side effects 
at the same time.
So far, only one study for CyberKnife lung SBRT has reported 
details on the GTV dose distribution (51) as suggested by the 
ICRU (50). Therefore, direct comparison between our and 
historical data remains difficult at this time. On the other hand, 
there has been increasing evidence that the central dose to the 
GTV significantly matters for LC (13, 37–39, 55, 56). As further 
prove, our LC rates were substantially higher compared to those 
studies using more homogeneous dose prescription (53, 58). 
This significantly substantiates the German Society for Radiation 
Oncology (DEGRO) guidelines on lung SBRT which prefer lower 
prescription dose in combination with in-homogeneous dose 
distribution in the PTV (6, 17).
Comparing to our previous results for liver metastases and 
lung tumors, which were all treated with direct tumor tracking 
and did not include the described ITV motion management 
technique (39), we noticed the need for minimally higher doses 
in order to keep high LC rates. This is likely a result of the dose 
reductions effects for the ITV plans caused by interplay effects 
(28) and by the fact that the MC dose was calculated on static 
3D CT instead of 4D CT (32–34). Nevertheless, we did not see 
any significant outcome differences between direct tracking, 
ITV with small motion and ITV with large motion which also 
seems to be in agreement with a large inter-institutional study 
(26). Likely reasons for non-significant differences in outcome 
being our margin, optimization and validation concept and our 
results oppose previous reports on the problems with CyberKnife 
spine tracking for lung tumors (31). For comparability of motion 
compensation techniques (i.e., direct tracking vs. ITV motion 
management), the maximum lesion dose (or iso-center dose for 
gantry-based SBRT) may also be a plausible metric, although 
it was not a significant predicting factor for intra-modal dose 
modeling using direct tracking alone with the CyberKnife (39). In 
the present joined evaluation that included direct and non-direct 
tumor tracking, we now found excellent agreement with previ-
ous large multi-institutional dose modeling studies for 90% local 
tumor control cutoff maximum doses of 181  Gy10 for primary 
lung tumors [compared to 176 Gy10 (13)] and 149 Gy10 [compared 
to 160 Gy10 (13)] for lung metastases. Those results also confirm 
the minimally higher necessary maximum doses for primary vs. 
secondary lung tumors and the demand for in-homogeneous 
dose in the PTV as compared to a homogeneous dose prescrip-
tion approach (53, 58). Yet still, distinct description and report-
ing of the dose distribution (50) and benchmark trials (17) are 
necessary for multi-institutional multi-technology comparison 
or pooled evaluation of SBRT for lung tumors.
Also in agreement with prior publications (8, 13, 55, 56) and 
different to liver SBRT (38), we did not find significantly better LC 
for any histology in the subgroup analysis for lung metastases. On 
the other hand, tumor volumes were a significant factor for LC 
in univariate analysis, but opposite the previous studies (5, 13), 
we found more local recurrences with smaller than with larger 
lesions. This further supports our hypothesis that an optimization 
with reduced PTV prescription dose (if necessary for adherence 
to normal tissue constraints) will not result in significant inferior 
LC as long as a minimum PTV encompassing BED10 of greater 
100.8 Gy10 and a high GTV mean BED10 of greater 162.0 Gy10 for 
robotic lung tumor SBRT regardless of the tracking method is 
maintained. Based on previous findings and subgroup analysis, 
the minimum PTV encompassing and the GTV mean BED10 may 
even be reduced to 79.2–89.7 and 151.2 Gy10, respectively, when 
direct tracking was used (39). However, such doses cannot be 
maintained for re-irradiation treatment due to the dose limits to 
the prior-irradiated critical organs (59) and hence it is no surprise 
that prior local irradiation was a significant predictor for worse 
LC, remaining a borderline significant factor in multivariate 
analysis (p = 0.05). Re-treatment of local or regional recurrences 
after SBRT is also more and more frequently performed (60–62) 
and in our study, 42.9% of the non-pre-SBRT-irradiated local 
recurrences (n = 6) were re-treated with robotic SBRT.
Progression-free and OS of 43.2 and 62.4%, respectively, at 
2  years and a median OS of 39.8  months for the whole group 
were comparable to, and even more favorable than other pub-
lished studies (4, 5, 7–9, 21–24, 51–54). Interestingly, though not 
surprisingly, we found significant higher early distant progression 
for lung metastases patients as the determination of a real oligo-
metastatic status in patients remains challenging (63). But we also 
found better long-term survival as the driving survival factor for 
primary inoperable lung cancer patients are co-morbidities for 
early stage and fast extra-pulmonary progression for advanced 
stage patients (1–3, 5). Predictive for progression-free and OS was 
the Karnofsky Index and tumor stage in the univariate analysis, 
confirming previous results (4). Histology was also a significant 
factor on OS prediction in the subgroup analysis for the lung 
metastases group and colorectal cancer patients seem to be in 
favor for long-term survival as repeatedly published (4, 8, 9).
Fiducial implantation remains a risk and should be avoided. In 
our study, 95.6% of the patients were treated fiducial-less which 
was higher compared to other recently published studies (23–25, 
31, 54). A fully non-invasive treatment approach for lung cancer 
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patients is, besides being highly effective, a significant advantage 
for SBRT compared to surgery (11) or other ablative techniques 
(10). In our study, 41.7% of the patients (n =  5) undergoing 
fiducial implantation experienced a minor pneumothorax which 
is similar to reports by other groups (21, 22). The pneumotho-
raxes were not as severe possibly because the use of the fine 
needle markers. Alternatively, bronchoscopically guided fiducial 
implantation may also reduce the pneumothorax risk, however, 
all our implantations where for peripheral lesions where such 
technique is challenging. Concerning radiation-induced toxici-
ties, we found only mild acute radiation pneumonitis grade 1–2 
in 4.8 and 0.5% chronic grade 2 rip fractures while grade 3 side 
effects were not observed. Our toxicity profiles compare very 
favorably with published reports as they range at the lowest spec-
trum of reported side effects (5, 7–9, 21–24, 48, 49, 51–54, 58). 
This importantly confirms our previously reported strategy of 
reducing the PTV prescription dose when necessary (e.g., for 
chest wall or for large lesions) while maintaining high mean GTV 
doses for high LC (38, 39).
Limitations to our findings are inherent to the retrospective 
nature of the study, even though we treated all patients accord-
ing to prospective study-like institutional guidelines including 
follow-up. The combined analysis of different tumor histology 
with various prior treatments also made thorough determination 
of predictive factors difficult. Furthermore, with the low number 
of events, especially for LC (n = 17), conclusions from the mul-
tivariate analysis need to be taken with caution. Larger patient 
cohorts, either collected as a multi-institutional registry or ideally 
enrolled in a prospective study with coherent patient criteria, 
longer follow-up periods and detailed patient and dosimetry 
information are needed in order to validate our assumptions and 
to define the patient groups significantly to benefit from SBRT.
cOnclUsiOn
Robotic SBRT is a safe and effective treatment for up to four 
lung tumors with minimal toxicities and high local tumor 
control rates. As long as GTV mean BED10 greater 162.0 Gy10 is 
maintained, regardless of the tracking method, a significantly 
lower PTV prescription BED10 compared to common published 
literature can be sufficient for high LC rates. Nevertheless, a 
reasonable minimum PTV prescription BED10 of greater than 
100.8 Gy10 is required despite the GTV mean dose optimization. 
The use of real-time motion compensation may potentially allow 
further, but minor dose reduced and is therefore strongly advised. 
Carefully performed ITV motion compensation may be used for 
selected group of patients without compromising the outcomes.
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